Related Experiment Video

Updated: May 21, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Can pharmacologic gradient reduction decrease mortality in hypertrophic cardiomyopathy?

Dan Musat1, Silviana Marineci, Mark V Sherrid

  • 1Valley Health System, (affiliate of Columbia University, College of Physicians and Surgeons), Ridgewood, NJ, USA.

Progress in Cardiovascular Diseases
|June 13, 2012
PubMed

Insights

Pharmacologic therapy can reduce obstructive hypertrophic cardiomyopathy (HCM) gradients. This review explores if gradient reduction in milder HCM cases may decrease mortality, though randomized trials are lacking.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Pharmacologic therapy is the primary approach for obstructive hypertrophic cardiomyopathy (HCM) symptom relief.
  • Surgical septal myectomy offers excellent prognosis but is reserved for severe, refractory cases.
  • No randomized trials exist to assess pharmacologic therapy's prognostic impact in HCM.

Purpose of the Study:

  • To review the potential benefits of pharmacologic gradient reduction in asymptomatic or mildly symptomatic obstructive hypertrophic cardiomyopathy (HCM) patients.
  • To evaluate if reducing the left ventricular outflow tract (LVOT) gradient pharmacologically may decrease HCM-related mortality.

Main Methods:

  • Review of existing literature on pharmacologic and surgical interventions for obstructive hypertrophic cardiomyopathy (HCM).
  • Analysis of studies evaluating gradient reduction therapies, including combined disopyramide and beta-blockade.
  • Examination of prognostic data related to gradient reduction in HCM.

Main Results:

  • Pharmacologic therapy is the first-line treatment for HCM symptoms.
  • Combined disopyramide and beta-blockade effectively reduces resting gradients, though less than surgery.
  • The prognostic impact of pharmacologic gradient reduction in milder HCM remains unevaluated by randomized trials.

Conclusions:

  • Surgical septal myectomy is associated with excellent prognosis for severe obstructive hypertrophic cardiomyopathy (HCM).
  • Pharmacologic management, particularly combined disopyramide and beta-blockade, can reduce gradients in HCM.
  • Further research, including randomized trials, is needed to determine if pharmacologic gradient reduction impacts mortality in patients with less severe obstructive hypertrophic cardiomyopathy (HCM).

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...